Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By ...

Mir195 enables Ebf1-deficient hematopoietic progenitor cells to mature into B cells, suggesting some miRNA can substitute for transcription factors in differentiation.

A collaborative study published in Immunity from the Batista Lab and Liu Lab at the Ragon Institute, together with the Schief ...

Most people have the Epstein-Barr (EBV) virus. Sometimes people are unaware of this virus in their body; it settles into immune cells and remains for the duration.

Officials, engineers and a consultant will jointly monitor timelines, quality and spending, centralise complaint tracking ...

A Northwestern Medicine study has shed light on one of the most intricate construction projects in biology: how cells build ...

Over 95% of the world’s adult population is infected with Epstein–Barr virus (EBV), but most people never realise it. The ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

The new version of CAR-T therapy has shown the ability to effectively destroy cancer cells in mice without suppressing the ...

Leonard Zon, professor of stem cell and regenerative biology and Grousbeck Professor of Pediatrics at Harvard Medical School, has been awarded the 2026 March of Dimes Richard B. Johnston Jr., MD Prize ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

The difficulty is that EBV lives latently in B cells in the blood at a frequency, in most immunocompetent individuals, of about 1 in 100,000 to 1 in a million. That level of infection is below the ...